Classification and Therapeutic Goal
Ivabradine, alongside alinidine and falipamil, represents a novel pharmacological group known as heart rate-lowering agents (bradycardic agents).
The primary therapeutic objective of these drugs is a reliable reduction in myocardial oxygen demand. This effect is achieved exclusively through the induction of bradycardia (slowing the heart rate), rather than by lowering blood pressure or depressing cardiac function.
A key advantage of this approach is that the drugs do not exert a negative inotropic effect (myocardial contractility is preserved). This property makes ivabradine a particularly valuable tool for treating patients in whom ischemia coexists with heart failure.
Mechanism of Action and Hemodynamic Effects
The site of action of ivabradine is strictly limited to the cells of the sinoatrial (SA) node. The drug does not affect Purkinje fibers, atrial cardiomyocytes, or atrioventricular (AV) node cells.
At the molecular level, the molecule acts as a selective blocker of $I_f$ channels (funny channels). The electrophysiological consequence of this blockade is the prolongation of the spontaneous diastolic depolarization phase. As a result, the sinoatrial node generates impulses less frequently, leading to bradycardia.
Unlike classical beta-blockers or calcium channel blockers, ivabradine acts in a highly isolated and specific manner:
- Conduction velocity: Not reduced (the drug does not slow intra-atrial, atrioventricular, or intraventricular conduction).
- Contractility: Not depressed (ventricular pumping and contractile function are fully preserved).
- Blood pressure: Not lowered (there is no risk of arterial hypotension).
Mechanism of the Antianginal Effect
Reducing the heart rate directly alters the duration of the phases of the cardiac cycle. Bradycardia predictably increases the duration of diastole—the period of cardiac relaxation.
It is precisely during this prolonged diastole that the most effective blood supply to the myocardium occurs. This mechanism achieves two important effects:
- The volume of main coronary blood flow increases.
- Collateral blood flow increases.
As a result, the heart muscle receives more oxygen under conditions of an initially reduced oxygen demand.
Pharmacokinetic Profile
The drug is administered orally (not used sublingually, rectally, or parenterally) and is absorbed in the gastrointestinal tract relatively quickly.
- Bioavailability: Approximately 40%.
- Distribution: Peak plasma concentration ($C_{max}$) is reached 1.5 hours after administration. About 70% of the active substance binds to plasma proteins.
- Metabolism: Occurs in the liver (rather than in plasma or kidneys) with the active participation of the cytochrome P-450 3A4 isoenzyme. Biotransformation yields an active metabolite—an N-demethylated derivative.
- Elimination: The half-life ($t_{1/2}$) is short, lasting exactly 2 hours. Metabolites are eliminated via two pathways: through the kidneys (in urine) and through the gastrointestinal tract (in feces).
Specific Adverse Effects
The most characteristic adverse effect of ivabradine involves the visual system: phosphenes. Patients may report altered light perception or sudden flashes of light in their visual field.
This phenomenon is explained by the fact that $I_f$ channels are present not only in the heart but also in retinal structures. Blockade of these receptors triggers visual anomalies.
It is important to note the drug's favorable safety profile in this regard:
- Ivabradine does not cause morphological (structural) changes in retinal blood vessels or the retina itself.
- Phosphenes are completely reversible. As a rule, they resolve spontaneously within 2 months, even if the patient continues therapy.